Eslampoor Alireza, Ehsaei Asieh, Abrishami Mojtaba
Cornea Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Tehran, Iran.
Clin Exp Ophthalmol. 2014 Dec;42(9):810-4. doi: 10.1111/ceo.12343. Epub 2014 May 8.
A major disadvantage of photorefractive keratectomy is postoperative pain and discomfort. This study aims to evaluate whether topical diclofenac 0.1% therapy adds any extra benefit to systemic diclofenac in controlling pain after photorefractive keratectomy.
Prospective randomized, double-masked clinical trial applied in the Khatam-al-Anbia Eye Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Sixty-eight individuals (age range, 18-35 years) having bilateral photorefractive keratectomy for myopic correction with or without astigmatism.
All patients received 100 mg of extended-release oral diclofenac two times (12-h interval) before photorefractive keratectomy surgery. Postoperatively, patients were randomized into the case and control groups. Case group was administered the diclofenac 0.1% drop, one drop 2 h preoperatively and four times daily postoperatively for 3 days, whereas the control group was given artificial tears instead.
Pain level, photophobia and functional activity were evaluated by the patient after operation.
Two days after surgery, no statistically significant difference in pain level was noted between both groups. In addition, photophobia and functional activity was not different between the case and control groups. Eyelid oedema and conjunctival injection levels were significantly higher in the control group (P < 0.001).
Administration of topical diclofenac to a standardized postoperative pain regime did not alleviate post-photorefractive keratectomy pain, although it is effective in local signs like eyelid oedema and conjunctival injection. It can be concluded that oral diclofenac is sufficient in the management of post-photorefractive keratectomy pain and addition of the topical diclofenac is unnecessary.
准分子激光原位角膜磨镶术的一个主要缺点是术后疼痛和不适。本研究旨在评估0.1%双氯芬酸局部用药在控制准分子激光原位角膜磨镶术后疼痛方面是否比双氯芬酸全身用药有额外益处。
前瞻性随机双盲临床试验,在伊朗马什哈德医科大学哈塔姆-安比亚眼科医院进行。
68名年龄在18至35岁之间、因近视矫正行双侧准分子激光原位角膜磨镶术(伴有或不伴有散光)的个体。
所有患者在准分子激光原位角膜磨镶术手术前12小时间隔两次口服100毫克缓释双氯芬酸。术后,患者被随机分为病例组和对照组。病例组术前2小时滴入0.1%双氯芬酸滴眼液一滴,术后每日4次,共3天,而对照组给予人工泪液。
术后由患者评估疼痛程度、畏光和功能活动情况。
术后两天,两组之间疼痛程度无统计学显著差异。此外,病例组和对照组之间畏光和功能活动情况也无差异。对照组的眼睑水肿和结膜充血程度明显更高(P < 0.001)。
在标准化的术后疼痛治疗方案中使用双氯芬酸局部用药并不能减轻准分子激光原位角膜磨镶术后的疼痛,尽管它对眼睑水肿和结膜充血等局部体征有效。可以得出结论,口服双氯芬酸足以管理准分子激光原位角膜磨镶术后疼痛,无需添加双氯芬酸局部用药。